These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19655363)

  • 1. The P86L common allele of CALHM1 does not influence risk for Alzheimer disease in Japanese cohorts.
    Inoue K; Tanaka N; Yamashita F; Sawano Y; Asada T; Goto YI
    Am J Med Genet B Neuropsychiatr Genet; 2010 Mar; 153B(2):532-535. PubMed ID: 19655363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CALHM1 P86L polymorphism is a risk factor for Alzheimer's disease in the Chinese population.
    Cui PJ; Zheng L; Cao L; Wang Y; Deng YL; Wang G; Xu W; Tang HD; Ma JF; Zhang T; Ding JQ; Cheng Q; Chen SD
    J Alzheimers Dis; 2010; 19(1):31-5. PubMed ID: 20061624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association between CALHM1 p.P86L variation and Alzheimer's disease in the Han Chinese population.
    Tao QQ; Sun YM; Liu ZJ; Yang P; Li HL; Lu SJ; Wu ZY
    Neurobiol Aging; 2014 Aug; 35(8):1956.e13-4. PubMed ID: 24630757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.
    Koppel J; Campagne F; Vingtdeux V; Dreses-Werringloer U; Ewers M; Rujescu D; Hampel H; Gordon ML; Christen E; Chapuis J; Greenwald BS; Davies P; Marambaud P
    Mol Med; 2011; 17(9-10):974-9. PubMed ID: 21629967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study.
    Lambert JC; Sleegers K; González-Pérez A; Ingelsson M; Beecham GW; Hiltunen M; Combarros O; Bullido MJ; Brouwers N; Bettens K; Berr C; Pasquier F; Richard F; Dekosky ST; Hannequin D; Haines JL; Tognoni G; Fiévet N; Dartigues JF; Tzourio C; Engelborghs S; Arosio B; Coto E; De Deyn P; Del Zompo M; Mateo I; Boada M; Antunez C; Lopez-Arrieta J; Epelbaum J; Schjeide BM; Frank-Garcia A; Giedraitis V; Helisalmi S; Porcellini E; Pilotto A; Forti P; Ferri R; Delepine M; Zelenika D; Lathrop M; Scarpini E; Siciliano G; Solfrizzi V; Sorbi S; Spalletta G; Ravaglia G; Valdivieso F; Vepsäläinen S; Alvarez V; Bosco P; Mancuso M; Panza F; Nacmias B; Bossù P; Hanon O; Piccardi P; Annoni G; Mann D; Marambaud P; Seripa D; Galimberti D; Tanzi RE; Bertram L; Lendon C; Lannfelt L; Licastro F; Campion D; Pericak-Vance MA; Soininen H; Van Broeckhoven C; Alpérovitch A; Ruiz A; Kamboh MI; Amouyel P
    J Alzheimers Dis; 2010; 22(1):247-55. PubMed ID: 20847397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium homeostasis modulator 1 gene P86L polymorphism and the risk for alzheimer's disease: A meta-analysis.
    Mun MJ; Kim JH; Choi JY; Jang WC
    Neurosci Lett; 2016 Apr; 619():8-14. PubMed ID: 26944452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CALHM1 P86L polymorphism is associated with late-onset Alzheimer's disease in a recessive model.
    Boada M; Antúnez C; López-Arrieta J; Galán JJ; Morón FJ; Hernández I; Marín J; Martínez-Lage P; Alegret M; Carrasco JM; Moreno C; Real LM; González-Pérez A; Tárraga L; Ruiz A
    J Alzheimers Dis; 2010; 20(1):247-51. PubMed ID: 20164592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CALHM1 and its polymorphism P86L differentially control Ca²⁺homeostasis, mitogen-activated protein kinase signaling, and cell vulnerability upon exposure to amyloid β.
    Moreno-Ortega AJ; Buendia I; Mouhid L; Egea J; Lucea S; Ruiz-Nuño A; López MG; Cano-Abad MF
    Aging Cell; 2015 Dec; 14(6):1094-102. PubMed ID: 26416646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of implication for CALHM1 P86L common variation in Italian patients with early and late onset Alzheimer's disease.
    Nacmias B; Tedde A; Bagnoli S; Lucenteforte E; Cellini E; Piaceri I; Guarnieri BM; Bessi V; Bracco L; Sorbi S
    J Alzheimers Dis; 2010; 20(1):37-41. PubMed ID: 20164602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALHM1 P86L polymorphism does not alter amyloid-beta or tau in cerebrospinal fluid.
    Giedraitis V; Glaser A; Sarajärvi T; Brundin R; Gunnarsson MD; Schjeide BM; Tanzi RE; Helisalmi S; Pirttilä T; Kilander L; Lannfelt L; Soininen H; Bertram L; Ingelsson M; Hiltunen M
    Neurosci Lett; 2010 Jan; 469(2):265-7. PubMed ID: 20005921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CALHM1 polymorphism is not associated with late-onset Alzheimer disease.
    Beecham GW; Schnetz-Boutaud N; Haines JL; Pericak-Vance MA
    Ann Hum Genet; 2009 May; 73(Pt 3):379-81. PubMed ID: 19472444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rare variants in calcium homeostasis modulator 1 (CALHM1) found in early onset Alzheimer's disease patients alter calcium homeostasis.
    Rubio-Moscardo F; Setó-Salvia N; Pera M; Bosch-Morató M; Plata C; Belbin O; Gené G; Dols-Icardo O; Ingelsson M; Helisalmi S; Soininen H; Hiltunen M; Giedraitis V; Lannfelt L; Frank A; Bullido MJ; Combarros O; Sánchez-Juan P; Boada M; Tárraga L; Pastor P; Pérez-Tur J; Baquero M; Molinuevo JL; Sánchez-Valle R; Fuentes-Prior P; Fortea J; Blesa R; Muñoz FJ; Lleó A; Valverde MA; Clarimón J
    PLoS One; 2013; 8(9):e74203. PubMed ID: 24069280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondria sense with different kinetics the calcium entering into HeLa cells through calcium channels CALHM1 and mutated P86L-CALHM1.
    Moreno-Ortega AJ; Ruiz-Nuño A; García AG; Cano-Abad MF
    Biochem Biophys Res Commun; 2010 Jan; 391(1):722-6. PubMed ID: 19944073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic association of CALHM1 rs2986017 polymorphism with risk of Alzheimer's disease: a meta-analysis.
    Lu Y; Liu W; Tan K; Peng J; Zhu Y; Wang X
    Neurol Sci; 2016 Apr; 37(4):525-32. PubMed ID: 26700797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association between CALHM1 and risk for Alzheimer dementia in a Belgian population.
    Sleegers K; Brouwers N; Bettens K; Engelborghs S; van Miegroet H; De Deyn PP; Van Broeckhoven C
    Hum Mutat; 2009 Apr; 30(4):E570-4. PubMed ID: 19191332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No association between CALHM1 variation and risk of Alzheimer disease.
    Minster RL; Demirci FY; DeKosky ST; Kamboh MI
    Hum Mutat; 2009 Apr; 30(4):E566-9. PubMed ID: 19191331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk.
    Dreses-Werringloer U; Lambert JC; Vingtdeux V; Zhao H; Vais H; Siebert A; Jain A; Koppel J; Rovelet-Lecrux A; Hannequin D; Pasquier F; Galimberti D; Scarpini E; Mann D; Lendon C; Campion D; Amouyel P; Davies P; Foskett JK; Campagne F; Marambaud P
    Cell; 2008 Jun; 133(7):1149-61. PubMed ID: 18585350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic association between CALHM1, 2, and 3 polymorphisms and Alzheimer's disease in a Japanese population.
    Shibata N; Kuerban B; Komatsu M; Ohnuma T; Baba H; Arai H
    J Alzheimers Dis; 2010; 20(2):417-21. PubMed ID: 20164573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CALHM1 variant is not associated with Alzheimer's disease among Asians.
    Tan EK; Ho P; Cheng SY; Yih Y; Li HH; Fook-Chong S; Lee WL; Zhao Y
    Neurobiol Aging; 2011 Mar; 32(3):546.e11-2. PubMed ID: 19545933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the CALHM1 G330D and R154H human variants on the control of cytosolic Ca2+ and Aβ levels.
    Vingtdeux V; Tanis JE; Chandakkar P; Zhao H; Dreses-Werringloer U; Campagne F; Foskett JK; Marambaud P
    PLoS One; 2014; 9(11):e112484. PubMed ID: 25386646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.